In specialist liver surgical centres, where patients are evaluated for liver resection, optimal management by MDT using KRAS testing, cetuximab and chemotherapy results in a 28% R0 resection rate in patients with initially unresectable colorectal cancer liver metastases.

tasis. The 1-and 5-year post-hepatic transplantation survival rates among patients subjected to bone scintigraphy were 81% and 69%, respectively; those among patients not subjected to scintigraphy were 78% and 62%, respectively (p = 0.25). The 1-and 5-year post-HTx recurrence rates among patients subjected to bone scintigraphy were 4.8% and 10.7%; those among patients not subjected to scintigraphy were 2.9% and 10.1%, respectively (p = 0.46). Results: The cost generated by the current evaluation policies, US$ 27.582, did not result in the detection of any sub-clinical metastasis and therefore failed to provide positive cost-effectiveness. ConClusions: Clinical evidence has demonstrated that bone scintigraphy did not provide aditional information about patient selection since the incidence of metastasis in early stages is very low. In our cohort, the use of scintigraphy in the assessment of patients with early stages of HCC and within the Milão criteria, included in a liver transplant list by dead donor, in a center in the south of Brazil, had zero benefit. objeCtives: To determine the cost-utility of continuing education for the management of patients with type 2 Diabetes Mellitus (T2DM), in Pernambuco -Brazil. Methods: It's a cost-utility evaluation, using the Markov model to simulate the results in health scenarios, from the perspective of the health system. It was considered an analytic horizon of 20 years and selected the category of direct medical costs. Data were obtained from primary source, SERVIDIAH study, and secondary sources from health information systems and literature. The reference scenario represents the standard health care management performed in public health services. The simulated scenarios for post-intervention's results were based on the suggestion of consulted experts in regard the effectiveness of continuing education for health professionals in primary health care (PHC) for the patient's complications reduction. Results: The average individual, representative Pernambuco's population, was female, 61 years old and diagnosed with T2DM for 8.7 years. These and other clinical characteristics that influence the calculation of the transition probabilities were gathered from over 800 patients with T2DM from Pernambuco.

No abstract

genitourinary (GU), and sexual toxicities were recorded according to the Radiation Therapy Oncology Group toxicity scoring criteria. Patients also completed the Expanded Prostate Cancer Index Composite (EPIC) questionnaires for quality of life every 6 months. Results: Median follow-up was 80 months (range 4.9-132 months). Median patient age was 68.5 years (range 51-83 years). The majority of patients had T1c or T2 clinical stage, 60.8% had a Gleason score of 7, and median prostate-specific antigen (PSA) was 9.3 ng/mL (range 3-24.4 ng/mL). Recurrence was observed in 5 patients who lead to a BF rate of 9.8%. The 5-year cancer-specific survival (CSS) and overall survival (OS) were 100% and 87.9%, respectively. The 11-year estimated CSS and OS were 85.3% and 67.8%, respectively. The Fisher exact test showed that the only significant predictor BF was Gleason score of 8. Late toxicity included grade 2 GI toxicity in 2 (5.9%) patients and no grade 3 GI toxicity; GU toxicity grades 2 and 3 in 3 (9%) and 5 (14.7%) patients, respectively; as well as erectile function grades 2 and 3 in 27 (31%) patients. Conclusion: These long-term outcomes confirm that hypofractionated EBRT plus HDR brachytherapy boost provides good results in terms of treatment-related toxicity and biochemical control for intermediate-to high-risk prostate cancer patients. We believe these findings support the use of HDR brachytherapy as a valuable dose escalation modality for localized prostate cancer.